Evidence map›Paper›PMID 34108675›Full record

ArticleBone marrow transplantation2021

Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation.

Ram Vasudevan Nampoothiri, Lina Ho, Cassandra McEwan, Ivan Pasic, Wilson Lam, Arjun Datt Law, Fotios V Michelis, Santhosh Thyagu, Dennis Dong Hwan Kim, Armin Gerbitz and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Post-Transplant Complications.Blood cell therapy · 2023
    Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Ram Vasudevan NampoothiriHans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Center, Toronto, ON, Canada.
Lina HoHans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Center, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-7033-4549
Cassandra McEwanHans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Center, Toronto, ON, Canada.
Ivan PasicHans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Center, Toronto, ON, Canada.
Wilson LamHans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Center, Toronto, ON, Canada.
Arjun Datt LawHans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Center, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-9251-3609
Fotios V MichelisHans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Center, Toronto, ON, Canada.
Santhosh ThyaguHans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Center, Toronto, ON, Canada.
Dennis Dong Hwan KimHans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Center, Toronto, ON, Canada.
Armin GerbitzHans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Center, Toronto, ON, Canada.
Auro ViswabandyaHans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Center, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-9690-4669
Jeffrey Howard LiptonHans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Center, Toronto, ON, Canada.
Jonas MattssonHans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Center, Toronto, ON, Canada.
Rajat KumarHans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Center, Toronto, ON, Canada. rajat.kumar@uhn.ca.ORCID http://orcid.org/0000-0002-4786-5699
Princess Margaret Cancer Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eltrombopag has shown efficacy in the treatment of thrombocytopenia and poor graft function (PGF) after allogeneic hematopoietic cell transplantation (HCT) in retrospective observational studies, but is not approved for this indication. The cost of this drug is also a major concern in publicly funded health care systems. We collected data about patients who received eltrombopag for thrombocytopenia or PGF after HCT. Post-HCT thrombocytopenia, PGF, and eltrombopag response were defined as per previously published criteria. Primary outcome was treatment efficacy and secondary outcome was cost comparison between estimated treatment cost prior to and after initiation of eltrombopag. Seventeen patients (males 70.6%; median age = 58) received eltrombopag. Isolated thrombocytopenia was present in 11.8% (n = 2) patients while PGF was present in 88.2% (n = 15) of patients. After 8 weeks of treatment at the maximum dose of 150 mg orally daily, overall response rate (ORR) was seen in 76.5% (13/17) of patients: complete response (CR) in 10/13 patients and partial response (PR) in 3/13 patients. The use of eltrombopag was associated with an overall decrease in the total weekly care costs (5021 vs 2,524 CA$; P = 0.04). Thus, Eltrombopag is an efficacious and possibly cost-effective therapy for thrombocytopenia and PGF after allogeneic HCT.

Indexed as

Hematopoietic Stem Cell TransplantationThrombocytopeniaBenzoatesCosts and Cost AnalysisHumansHydrazinesMaleMiddle AgedPyrazolesRetrospective StudiesBenzoateseltrombopagHydrazinesPyrazoles

Identifiers

PMID34108675
OpenAlexW3170796831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.